Modern approaches to the treatment of gastric neuroendocrine tumors


如何引用文章

全文:

详细

Gastrointestinal neuroendocrine tumors (GI-NETs) include a wide range of tumors with different variants of the course of the disease. At the one end of the clinical spectrum there are highly differentiated type I GI-NETs, with five-year survival rate over 95%, at the another end there are low-differentiated neuroendocrine carcinoma (large-, smallcell cancers) representing a tumor with extremely poor prognosis. Therapeutic approaches to different types of tumors are different. It is necessary to distinguish the treatment of well-differentiated neuroendocrine neoplasms (I and II clinical-morphological type) and low-differentiated neuroendocrine carcinomas. At the same time, it should be noted how different is the treatment of well-differentiated neuroendocrine tumors with high proliferative activity index (III clinico-morphological type of tumor) and low-differentiated neuroendocrine carcinomas (large-, small-cell cancers).

作者简介

Ivan Peregorodiev

N.N. Blokhin Russian Cancer Research Center

Email: ivan.peregorodiev@gmail.com
MD, postgraduate student of the Department of аbdominal oncology Moscow, 115478, Russian Federation

V. Bokhian

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

I. Stilidi

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

V. Delektorskaya

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

参考

  1. Перфильев И.Б., Кувшинов Ю.П., Унгиадзе Г.В., Малихова О.А., Поддубный Б.К., Делекторская В.В. и др. Междисциплинарный подход в диагностике и лечении нейроэндокринных опухолей желудка. В кн.: Материалы XVII Российско-Японского симпозиума: «Воспоминание о будущем эндоскопии», 19-21 февраля 2015 года, Москва.
  2. Oberg K. Management of neuroendocrine tumours. Ann. Oncol. 2004; 15 (Suppl 4): 293-8.
  3. Delle Fave G., Kwekkeboom D.J., Van Cutsem E., Rindi G. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012; 95: 74-87.
  4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) NCCN.org
  5. Basuroy R., Srirajaskanthan R., Prachalias A. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment. Pharmacol. Ther. 2014; 39(10): 1071-84.
  6. Borch K., Ahren B., Ahlman H. et al. Gastric carcinoids biologic behavior and prognosis after differentiated treatment in relation to type. Ann. Surg. 2005; 242: 64-73.
  7. Crosby D.A., Donohoe C.L., Fitzgerald L., Muldoon C., Hayes B., O’Toole D., Reynolds J.V. Gastric neuroendocrine tumours. Dig. Surg. 2012; 29: 331-48.
  8. Ahlman H., Kolby L., Lundell L., Olbe L., Wängberg B., Granérus G. et al. Clinical management of gastric carcinoid tumors. Digestion. 1994; 55 (Suppl. 3): 77-85.
  9. Schindl M., Kaserer K., Niederle B. Treatment of gastric neuroendocrine tumors: necessity of a type-adapted treatment. Arch. Surg. 2001; 136: 49-54.
  10. Campana D., Nori F., Pezzilli R., Piscitelli L., Santini D., Brocchi E. et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr. Relat. Cancer. 2008;1 5: 337-42.
  11. Jianu C.S., Fossmark R., Syversen U., Hauso O., Fykse V., Waldum H.L. Five-year follow-up of patients treated for 1 year with octreotide longacting release for enterochromaffin-like cell carcinoids. Scand. J. Gastroenterol. 2011; 46: 456-63.
  12. Merola E., Sbrozzi-Vanni A., Panzuto F. et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012; 95(3): 207-13.
  13. Ramage J.K., Ahmed A., Ardill J., Bax N., Breen D.J., Caplin M.E. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61: 6-32.
  14. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann. Oncol. 2001; 12 (Suppl 2): S111-14.
  15. Kvols L.K., Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors. Am. J. Med. 1987; 82: 77-83.
  16. Christopoulos C., Papavassiliou E. Gastric neuroendocrine tumors: biology and menegement. Ann. Gastroenterol. 2005; 18(2): 127-40.
  17. Oberg K. Management of neuroendocrine tumors: current and future therapies. Expert. Rev. Endocrinol. Metab. 2011; 6(1): 49-62.
  18. Arai K., Matsuda M. Gastric small-cell carcinoma in Japan: a case report and review of the literature. Am. J. Clin. Oncol. 1998; 21(5): 458-61.
  19. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002; 346: 85-91.
  20. Okita Tsuda N., Kato K., Takahari D., Hirashima Y., Nakajima T.E., Matsubara J. et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011; 14: 161-5.
  21. Nilsson O., van Cutsem E., Delle Fave G., Yao J.C., Pavel M.E., McNicol A.M. et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology. 2006; 84(3): 212-5.
  22. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J. Surg. 1996; 20: 203-7.
  23. Kölby L., Bernhardt P., Sward C., Johanson V., Ahlman H., Forssell-Aronsson E. et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Reg. Pept. 1991, 120: 269-73.
  24. Modlin I.M., Moss S.F., Oberg K., Padbury R., Hicks R.J., Gustafsson B.I. et al. Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med. J. Aust. 2010; 193: 46-52.
  25. Rinke A., Müller H.-H., Schade-Brittinger C., Klose K.-J., Barth P., Wied M. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 2009; 27(28): 4656-63.
  26. Jensen R.T., Berna M.J., Bingham D.B., Norton J.A. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008; 113(7, Suppl.): 1807-43.
  27. Castellano D., Bajetta E., Panneerselvam A., Saletan S., Kocha W., O’Dorisio T. et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study. Oncologist. 2013; 18(1): 46-53.

版权所有 © Eco-Vector, 2016


 


##common.cookie##